Animal-model studies used to predict vaccine efficacy in humans are challenging because direct extrapolation of experimental results to humans is not possible for a number of reasons. Interspecies differences in pathogen-recognition receptors may explain differences between humans and rodents in the response to microbial vaccines. There are also species-specific B-cell and T-cell repertoires, as well as HLA presentation of dominant epitopes to CD4 and CD8 T cells. Because of these limitations, studies of candidate vaccines are conducted in several species of small and large animals, which is expected to yield data more transferable to humans. The aim of this study was a comparative assessment in mice and guinea pigs of the protective effect of the differing in antigenic composition 231ΔnlpD and EVΔlpxM plague pathogen strains upon a single immunization with them separately or in a mixture. Materials and methods. The protectivity of the studied strains was characterized by the immunity index in subcutaneous infection of mice and guinea pigs. Results. As in previous experiments [1], the introduction of monopreparations based on attenuated 231ΔnlpD or EVΔlpxM strains selectively induced protection only in mice or guinea pigs, respectively. Immunization with a mixture of attenuated strains provided an immunity index of more than 108 for both types of laboratory animals. Conclusion. Single-stage subcutaneous immunization of mice and guinea pigs with attenuated Y. pestis strains 231ΔnlpD and EVΔlpxM enhances immunity to plague following subcutaneous challenge with wild-type strain 231.
11 February 2023 in Problems of Particularly Dangerous Infections
The aim of the work was to put forward the methods for direct quantitative determination of the content of Yersinia pestis and Rickettsia raoultii protein antigens in preparations and various prototypes of subunit vaccines. Materials and methods. Y. pestis LcrV and Caf1 antigens enclosed in the substance of the molecular microencapsulated plague vaccine (MMPV) and separately, in microcrystals of amino acids co-precipitated with plague proteins were used as model antigens. R. raoultii Adr2, OmpB24, and YbgF antigens were adsorbed on the prototype substance of the rickettsia vaccine. The release of plague antigens from MMPV microcapsules was carried out through successive treatment of the latter with organic solvents, methylene chloride and methanol, respectively; the carrier microcrystals were dissolved in 0.1 M sodium citrate buffer at pH 6.0. The antigen content in the prototype substance of the rickettsial vaccine was determined by measuring the amount of proteins not bound to the alumogel. Quantitative parameters characterizing the content of antigens in the substances and prototypes of vaccine preparations were calculated by processing digital images of polyacrylamide gels obtained by electrophoresis of protein antigen fractions extracted from carriers. Results anddiscussion. Methods for direct extraction and subsequent quantitative analysis of Y. pestis LcrV and Caf1 antigens from subunit vaccine preparations based on amino acid microcrystals and polylactide microcapsules that do not cause protein degradation have been studied. A different nature of the binding of LcrV and Caf1 in the substances of microcrystals has been established, while the proportion of antigens released from microcrystals has been quantified only in case of their complete dissolution. It was found that at low concentrations of LcrV and Caf1 proteins extracted from microcrystals, it is necessary to concentrate the extracts with subsequent removal of salts for their reliable visualization. It has been confirmed that 10 μg of plague antigens and proteins of R. raoultii in a dose volume of 200 μl of suspension is sufficient for quantitative analysis using electrophoretic method. The prospects of other physicochemical methods alternative to direct extraction of antigens for evaluating the composition and quality of vaccine preparations are discussed.
1 June 2025 in Molecular Genetics, Microbiology and Virology
Animal model studies used to predict vaccine efficacy in humans present a considerable challenge, as direct extrapolation of experimental results to humans
Yersinia pestis caused the three plague pandemics that claimed more than two hundred million human lives. There is still no vaccine that meets all WHO requirements, and many researchers continue to develop plague vaccines using various technological platforms. For example, researchers led by Roy Curtiss 3rd have developed a new approach to achieve controlled, delayed attenuation of bacterial pathogens. Mutants generated using this method were superior in protecting Y. pestis-infected mice immunized with strains generated using traditional gene knockout. However, further studies are needed to determine the safety and efficacy of these delayed-attenuated strains in other mammalian species in order to extrapolate on humans the data obtained in accordance with the FDA Animal Rule. Three Y. pestis strains, a Δcrp mutant, a mutant with arabinose-dependent regulated crp expression (araC PBADcrp) or an araC PBADcrp mutant cured of plasmid pPst were derived from virulent wild-type strain 231. To evaluate the safety, outbred mice or guinea pigs were immunized subcutaneously with serial tenfold dilutions of mutated strains. For vaccine studies, immunized animals were subcutaneously challenged with 200 LD100 (lethal dose in all exposed subjects) of the wild-type Y. pestis strain. The challenge caused the death of 100% of naïve animals in controls. The Y. pestis strain 231Δcrp was nonlethal in mice at a dose of 107 CFs. The LD50 of the 231Δcrp strain in guinea pigs increased by at least 107-fold compared to that of the wild-type strain. The LD50s of the 231PBAD-crp mutant in mice and guinea pigs were approximately 104-fold and 107-fold higher than those of Y. pestis 231, respectively. The 231PBAD-crp(pPst¯) strain did not cause death in mice (LD50 > 107 CFU) and guinea pigs (LD50 > 109 CFU) when administered subcutaneously and was capable of inducing intense protective immunity in both species of laboratory animals. Our research has shown once again the necessity of balance between safety and effectiveness demonstrating the feasibility of further investigation of crp mutants as promising candidate plague vaccines.